📊 This includes the Maverick, Maven, Rebel, and ZipChip instruments.
🔍 These devices enhance Repligen’s process analytical technology (PAT) offerings, improving manufacturing efficiency.
🤝 Both companies are focused on advancing their respective technologies in bioprocessing and health applications.
Introduction:
The article discusses Repligen’s recent acquisition of 908 Devices’ bioprocess analytics portfolio, aimed at enhancing Repligen’s capabilities in bioprocessing applications. This acquisition signifies a strategic move to bolster Repligen’s analytics portfolio, thus addressing the increasing demands in the biopharmaceutical manufacturing sector.
- Repligen has acquired a desktop portfolio of four analytical devices from 908 Devices, specifically for bioprocessing applications.
- The devices included in the acquisition are MAVERICK, MAVEN, REBEL, and ZipChip, each serving critical functions in monitoring, control, and characterization of bioprocess parameters.
- This addition strengthens Repligen’s existing Process Analytical Technology (PAT) portfolio, providing customers with actionable insights to optimize development processes.
- Both companies expressed optimism regarding the synergies created by the acquisition, with 908 Devices focusing on its handheld device portfolio for health and safety applications.
- The transaction was valued at $70 million, reflecting Repligen’s commitment to expanding its technological innovations in the bioprocessing field.
Conclusion:
This acquisition is a strategic advancement for Repligen, allowing it to enhance its analytics offerings and integrate innovative solutions across the bioprocess workflow. As the industry increasingly adopts digitization in production, this acquisition positions Repligen favorably for future growth and technological leadership in bioprocessing analytics.
